Case reports in gastroenterology
Cure8 research brief
Why This Matters
Distinguishing Crohn’s disease from gastrointestinal tuberculosis is difficult in TB-endemic areas and can delay correct treatment. Persistent ileocolonic inflammation after full antituberculosis therapy plus negative TB testing should prompt reassessment for Crohn’s disease.
Who Should Pay Attention
Clinicians (gastroenterology, infectious disease), adult patients in TB-endemic regions, patients with persistent ileocolonic inflammation despite TB therapy.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The report highlights key clues prompting reevaluation when intestinal tuberculosis is suspected: persistent endoscopic ulcers and strictures after adequate TB therapy, repeatedly negative intestinal TB tests (PCR and AFB stains), and histologic features such as cryptitis, crypt abscesses, and non-necrotizing granulomas that favored Crohn’s disease.
The patient improved clinically and by fecal calprotectin after starting mesalamine and ustekinumab, and follow-up colonoscopy showed marked healing.
Keep In Mind
Single case report summarized from the article abstract; does not provide generalizable evidence. Diagnostic reassessment and treatment choices require clinical judgment and guideline consultation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCase reports in gastroenterology
AuthorsDela Peña JP, Francisco CPD, Francisco MD +1 more
Study typeJournal article, case reports
Indexed viaEurope PMC
Source typeResearch paper
PublishedJan 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Multimodal monitoring of pan-enteric mucosal healing and biologic persistence in Crohn's disease-the MILESTONE-CD prospective cohort.
Measuring mucosal healing across the whole gut with stool markers, ultrasound, and capsule endoscopy may give a clearer picture of whether biologic treatment is working and help guide decisions about continuing or...
Ustekinumab Dose Intensification Safe in Inflammatory Bowel Disease Cohort | AGA
Shortening ustekinumab dosing intervals raised drug levels and was associated with high rates of steroid-free clinical remission in this small prospective IBD cohort, offering a practical option for patients who lose...
Understanding role of microbiota in Crohn's disease, ulcerative colitis
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...